報價延遲最少15分鐘:2025/05/30 17:01 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.5 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.89/-3.28
|
|
企業價值
418.56M
|
| 資產負債 |
|
每股賬面淨值
6.80
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
5.00M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/30 17:01 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. |